İNOTUZUMAB VE İNOTUZUMAB+MİNİ HYPERCVAD PROTOKOLLERİ
Kaynaklar:
1- Kantarjian H, Thomas D, Jorgensen J, et al. . Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403-411.
2- Kantarjian H, Thomas D, Jorgensen J, et al. . Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728-2736.
3- Kantarjian HM, DeAngelo DJ, Stelljes M, et al. . Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740-753.
4- Yurkiewicz IR, Muffly L, Liedtke M. Inotuzumab ozogamicin: a CD22 mAb‐drug conjugate for adult relapsed or refractory B‐cell precursor acute lymphoblastic leukemia. Drug Des Devel Ther. 2018;12:2293‐2300.
5- DeAngelo DJ, Stock W, Stein AS, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22‐positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017;1:1167‐1180.
6- Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low‐intensity chemotherapy for older patients with Philadelphia chromosome–negative acute lymphoblastic leukaemia: a single‐arm, phase 2 study. Lancet Oncol. 2018;19:240‐248.
7-Pfizer Inc. BESPONSA® (inotuzumab ozogamicin) prescribing information. New York: Wyeth Pharmaceuticals; c2017 [last update Mar 2018]. http://labeling.pfizer.com/ShowLabeling.aspx?id=9503. Accessed Jan 2020.
8- European Medicines Agency. BESPONSA® (inotuzumab ozogamicin) summary of product characteristics. London: EMA; c2017 [last update Nov 25, 2019]. https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa. Accessed Jan 2020.
9- DeAngelo DJ, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017;1:1167–1180.
10- Kantarjian HM, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125:2474–2487.
11- Jabbour E, et al. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk. Res. 2020;88:106283.
12-Jabbour E, et al. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017;123:294–302.
13- Eckert C, et al. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96. Eur. J. Cancer. 2013;49:1346–1355.
14- Bertamini L, et al. Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia. BMC Cancer. 2018;18:1117.
15- Kantarjian HM, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4:e387–e398.
16- Marks DI, et al. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia. Biol. Blood Marrow Transplant. 2019;25:1720–1729.
17- Kebriaei P, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018;53:449–456.
18- Hoelzer D, et al. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2016;27:v69–v82.
19-Marks DI, et al. Burden of hospitalization in acute lymphoblastic leukemia patients treated with inotuzumab ozogamicin versus standard chemotherapy treatment. Cancer Med. 2019;8:5959–5968.
